Sm08502-onc-01
WebbA Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid … WebbCancer stem cells (CSCs) are a subpopulation of tumor cells that can drive tumor initiation and can cause relapses. These cells are seen as drivers of tumor establishment and growth, often correlated to aggressive, heterogeneous and therapy-resistant tumors. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) specifically …
Sm08502-onc-01
Did you know?
Webb[VIRTUAL] SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate … WebbSM08502, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects as Monotherapy and in …
WebbORG STUDY ID : SM08502-ONC-01 NCT ID : NCT03355066 Conditions Solid Tumor, Adult Interventions Purpose This study is an open-label, multi-center, dose-escalation, dose … WebbCANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment Salubris Biotherapeutics Announces …
Webb17 nov. 2024 · Drug: SM08502 Study Type Interventional Enrollment (Actual) 82 Phase Phase 1 Contacts and Locations This section provides the contact details for those … WebbThe Botanical Supplements Market is Estimated to Reach a Market Size Worth us$39.767 Billion by 2027 United States Liquid Biopsy Market Expected to Grow at Double-Digit …
Webb28 nov. 2024 · A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors The safety and scientific validity of …
Webb31 mars 2024 · SM08502 is a first-in-class CLK inhibitor being investigated in a Phase 1 clinical trial for subjects with advanced solid tumors (NCT03355066). Keywords: … coconut and chocolate chip barsWebb6 jan. 2024 · SM08502 inhibited the Wnt signaling pathway, both in vitro and in vivo, in colorectal cancer models. Inhibition of CLK2 and CLK3 affected alternative splicing, which underlies inhibition of aberrant Wnt signaling. SM08502 also demonstrated significant anti-tumor effects in xenograft models of gastrointestinal cancer. calluses pronunciationWebbSM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate cancer … coconut and chocolate cookie recipeWebb15 juni 2024 · DKN-01和PD-1抑制剂pembrolizumab（Keytruda）的组合最近在具有高DKK1表达的胃食管腺癌患者中显示出了希望。 ... SM08502. SM08502是CLK2 / 3的抑 … calluses on feet cureWebbOmipalisib C25H17F2N5O3S CID 25167777 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities ... calluses on vocal cordsWebb27 jan. 2024 · SAN DIEGO, Jan. 27, 2024 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK … coconut and cherry small cakesWebb1 sep. 2024 · Characterization of SM08502, a small-molecule CLK inhibitor of Wnt activity. (A) SM08502 inhibited the activity of CLK kinases. CLK2, CLK3, and CDK1 kinase IC 50 s … calluses on the hands